Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 12, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- Aug 12, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Jun 22, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record29319 flagged findings
Reported transactions (Form 4)80since Jan 31, 2025 · and 2 other holdings
Corporate events (8-K)8since Apr 19, 2021
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-12capital return (buybacks/dividends)recentOpen filing ↗“…in April 2025, our Board authorized a program to repurchase shares of our common stock (“Common Stock”). Under this…”
+1 more passage from the same document
- “…the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV or any other product candidates, we expect we will also incur…”
- 2026-05-12regulatory investigationrecentOpen filing ↗“…civil or criminal penalties; • suspend or withdraw regulatory approval; • suspend any of our clinical trials; • refuse to…”
- 2026-05-12Department of Justice inquiryrecentOpen filing ↗“…Compliance Matters We are subject to extensive and costly government regulation. Our product candidates will be subject to extensive…”
- 2026-03-05capital return (buybacks/dividends)recentOpen filing ↗“…HCV or any other product candidates, we expect we will also incur substantial expenses in connection with the establishment of…”
+1 more passage from the same document
- “…expenses in connection with the establishment of sales, marketing, internal systems and distribution infrastructure to…”
- 2026-03-05regulatory investigationrecentOpen filing ↗“…civil or criminal penalties; • suspend or withdraw regulatory approval; • suspend any of our clinical trials; 69 • refuse to…”
- 2026-03-05Department of Justice inquiryrecentOpen filing ↗“…Compliance Matters We are subject to extensive and costly government regulation. Our product candidates will be subject to extensive…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 293)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 6, 26SCHEDULE 13G ↗Passive stake · TANG CAPITAL MANAGEMENT, LLC · 6.0%
- Aug 12, 2610-Q ↗Quarterly report
- Aug 12, 268-K ↗Current report · Results
Insider transaction · 8 Form 4 filingsshow all 8hide
- Jun 22, 268-K ↗Current report · Shareholder vote results
- May 21, 26Form 4/A ↗Insider transaction · amendment
- May 20, 26Form 4 ↗Insider transaction
- May 12, 2610-Q ↗Quarterly report
- May 12, 268-K ↗Current report · Results
- May 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 15.0% · event on Mar 31, 26 · amendment
- Apr 27, 26DEFA14A ↗Shareholder meeting and votes
- Apr 27, 26DEF 14A ↗Shareholder meeting and votes
- Mar 26, 26SCHEDULE 13G/A ↗Passive stake · amendment
- Mar 13, 26Form 4 ↗Insider transaction
- Mar 5, 2610-K ↗Annual report
- Mar 5, 268-K ↗Current report · Results
- Feb 9, 26SCHEDULE 13G ↗Passive stake · Leonard Braden Michael · 9.9% · event on Dec 31, 25
- Feb 3, 26Form 4 ↗Insider transaction
293 filings on record, the oldest from Jul 16, 20.
Listing the 25 most recent filings of the 293 on record.
44
- Apr 17, 25Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Feb 24, 25A senior executive left or was appointed8-K 5.02 ↗
- Nov 16, 21A material agreement was terminated8-K 1.02 ↗
- Jul 23, 21Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- May 20, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 19, 21A senior executive left or was appointed8-K 5.02 ↗
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Leonard Braden Michael8.5%Dec 13, 24SCHEDULE 13D ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Radoff Bradley Louis4.0%Apr 16, 25SCHEDULE 13D/A ↗10 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- FMR LLC15.0%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Jean-Pierre Sommadossi10.1%Mar 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Leonard Braden Michael9.9%Dec 31, 25SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- BlackRock, Inc.7.1%Mar 31, 25SCHEDULE 13G/A ↗
- TANG CAPITAL MANAGEMENT, LLC6.0%Oct 6, 26SCHEDULE 13G ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
show one more holderhide
- EcoR1 Capital, LLC4.0%Dec 31, 24SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Stock compensation, tax and giftsshow the 38 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Jun 18, 26Compensationamount n/aPolly A. Murphy↗
- Jun 18, 26Compensationamount n/aBruce Polsky↗
- Jun 18, 26Compensationamount n/aJerome M. Adams↗
- Jun 18, 26Compensationamount n/aBARBARA GAYLE DUNCAN↗
- Jun 18, 26Compensationamount n/aFRANKLIN M BERGER↗
- Jun 18, 26Compensationamount n/aBruno Lucidi↗
- Mar 11, 26Compensation$74KAndrea CorcoranSee Remarks↗
- Feb 3, 26Compensation$372KJean-Pierre SommadossiPresident, CEO, and Chairman↗
- Jan 31, 26Compensationamount n/aWayne FosterEVP, Chief Accounting Officer↗
- Jan 31, 26Tax$51KWayne FosterEVP, Chief Accounting Officer↗
- Jan 31, 26Compensationamount n/aJean-Pierre SommadossiPresident, CEO, and Chairman↗
- Jan 31, 26Tax$450KJean-Pierre SommadossiPresident, CEO, and Chairman↗
- Jan 31, 26Compensationamount n/aAndrea CorcoranSee Remarks↗
- Jan 31, 26Tax$68KAndrea CorcoranSee Remarks↗
- Jan 31, 26Compensationamount n/aJanet MJ HammondChief Development Officer↗
- Jan 31, 26Tax$60KJanet MJ HammondChief Development Officer↗
- Jan 31, 26Compensationamount n/aJohn VavrickaChief Commercial Officer↗
- Jan 31, 26Tax$49KJohn VavrickaChief Commercial Officer↗
- Jan 31, 26Compensationamount n/aMaria Arantxa HorgaChief Medical Officer↗
- Jan 31, 26Tax$68KMaria Arantxa HorgaChief Medical Officer↗
- Jun 20, 25Compensationamount n/aBruno Lucidi↗
- Jun 20, 25Compensationamount n/aBruce Polsky↗
- Jun 20, 25Compensationamount n/aFRANKLIN M BERGER↗
- Jun 20, 25Compensationamount n/aPolly A. Murphy↗
- Jun 20, 25Compensationamount n/aJerome M. Adams↗
- Jun 20, 25Compensationamount n/aBarbara Gayle Duncan↗
- Jan 31, 25Compensationamount n/aWayne FosterEVP, Chief Accounting Officer↗
- Jan 31, 25Compensationamount n/aWayne FosterEVP, Chief Accounting Officer↗
- Jan 31, 25Tax$37KWayne FosterEVP, Chief Accounting Officer↗
- Jan 31, 25Compensationamount n/aJean-Pierre SommadossiPresident, CEO, and Chairman↗
- Jan 31, 25Compensationamount n/aJean-Pierre SommadossiPresident, CEO, and Chairman↗
- Jan 31, 25Tax$271KJean-Pierre SommadossiPresident, CEO, and Chairman↗
- Jan 31, 25Compensationamount n/aAndrea CorcoranSee Remarks↗
- Jan 31, 25Compensationamount n/aAndrea CorcoranSee Remarks↗
- Jan 31, 25Tax$49KAndrea CorcoranSee Remarks↗
- Jan 31, 25Compensationamount n/aMaria Arantxa HorgaChief Medical Officer↗
- Jan 31, 25Compensationamount n/aMaria Arantxa HorgaChief Medical Officer↗
- Jan 31, 25Tax$49KMaria Arantxa HorgaChief Medical Officer↗
The full record holds 72 transactions and goes back to Jan 31, 23.
Its sector and its market
Atea Pharmaceuticals Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Atea Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Atea Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 293 documents on file, from Jul 16, 2020 to Oct 6, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 18, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.